The promise of CD30-targeting cellular therapies in HL

Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphomaПодробнее

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCLПодробнее

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HLПодробнее

‘Off-the-shelf’ EBV-specific CAR-T cells for Hodgkin lymphomaПодробнее

The promise of cellular therapies in Hodgkin lymphoma and future outlooksПодробнее

The role of cellular immunotherapies in the future treatment of HLПодробнее

CD30, a promising target for CAR-T therapy in Hodgkin lymphomaПодробнее

CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin LymphomaПодробнее

How NK therapies are transforming the treatment landscape of Hodgkin lymphomaПодробнее

Symposium | Targeted therapies for classic Hodgkin lymphomaПодробнее

Challenges in treating patients with HL who relapse after autoSCT & novel therapies being exploredПодробнее

Lymphoma cellular therapy updateПодробнее

Novel developments in relapsed/refractory HL: checkpoint inhibitors, bispecifics and CAR-T cellsПодробнее

New agents and therapeutic options for T-cell lymphomaПодробнее

Professor Malcolm K Brenner - Overview of cell therapy for cancer in 2022 and beyondПодробнее

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?Подробнее

Treating Patients With CD30-Positive PTCLПодробнее

Infusion of CD30 CAR T-cells following AuHCT in patients with lymphomaПодробнее

Revolutionizing Resistant Cancers: The Promise of T-Cell TherapyПодробнее